• Carvolix agreed a structured debt financing of up to EUR 30 million with Claret Capital to fund growth.
• Four-tranche package; EUR 10 million senior secured convertible bonds drawn immediately; a second EUR 10 million tranche hinges on FDA 510(k) clearance for Tavipilot.
• Package includes up to EUR 10 million senior secured amortised bonds; warrants issued valued at EUR 1.15 million; maximum dilution capped at 8.6%.
• Tranche A carries 10% fixed interest, paid monthly; principal grace period runs to June 30, 2029; maturity June 30, 2030.
• Proceeds earmarked for Tavipilot commercialization, portfolio development including Kalios, working capital; cash runway seen through February 2027 post-drawdown.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carvolix SA published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.